Progressive Ataxia and Cognitive Impairment Associated With SEZ6L2: Serum Neurofilament Light Chain as a Biomarker of Disease Activity
Abstract
ABSTRACT Introduction Autoimmune encephalitis (AE) associated with SEZ6L2 antibodies is a rare neurological disorder characterized by subacute onset of cerebellar ataxia, cognitive dysfunction, and extrapyramidal features. Few cases have been reported, and data on long‐term course and treatment response remain limited. Case Presentation A 64‐year‐old woman developed progressive cerebellar ataxia, cognitive decline, and psychiatric symptoms starting insidiously after SARS‐CoV‐2 pneumonia in September 2022. Magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis almost 1 year after onset were unremarkable. Due to progressive symptoms, she was admitted to our department in December 2024. Examination showed severe truncal and gait ataxia, memory impairment, and prominent frontal‐executive dysfunction. Brain MRI demonstrated bilateral hippocampal T2 hyperintensity with severe medial temporal lobe and cerebellar atrophy. Neuronal antibody testing with a tissue‐based assay (TBA) optimized for surface antigens showed strong neuropilar hippocampal and cerebellar staining in serum and CSF. A specific live cell‐based assay (CBA) confirmed that the reactivity could be attributed to SEZ6L2 antibodies. Plasmapheresis and high‐dose corticosteroids resulted in stabilization of gait impairment and mild cognitive improvement. Longitudinal plasma neurofilament light chain (NFL) monitoring showed initially high levels (85.12 pg/mL), followed by a drastic reduction some months after immunotherapy. Conclusions AE can mimic neurodegenerative processes, and SEZ6L2 antibody testing should be considered in patients with progressive ataxia and limbic involvement, even when no additional clues point towards an autoimmune etiology. Notably, the condition manifested a partial response to immunotherapy, supported by NFL reduction. This suggests that NFL might represent a useful biomarker to monitor disease activity in these conditions.